Peptistar reported that it has integrated Asahi Kasei’s forward osmosis–membrane distillation (FO–MD) system into manufacturing-scale trial production for peptides and oligonucleotide active pharmaceutical ingredients. The system concentrates liquids without applying heat or pressure, aiming to reduce reliance on freeze-drying and shorten API manufacturing time. The report emphasizes the manufacturing challenge for heat-sensitive next-generation modalities, where conventional solvent removal and concentration can introduce quality degradation or precipitates. FO–MD is presented as a mild alternative to technologies such as vacuum distillation that can risk solvent-composition-driven changes. By moving the FO–MD process into its facility, Peptistar is testing its readiness for GMP production, reflecting how CMO attention is shifting from formulation science to process intensification and time-to-batch in biologics-adjacent supply chains.